Skip to content

Emergent Biosolutions EBS Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
Opko Health logo
Opko HealthOPK
Medline, Inc.
 logo
Medline, Inc. MDLN
Charles River Laboratories logo
Charles River LaboratoriesCRL
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's amortization of capitalized software and acquired intangible assets?
Emergent Biosolutions (EBS) reported amortization of capitalized software and acquired intangible assets of $16.5M in Q1 2026.
How has Emergent Biosolutions's amortization of capitalized software and acquired intangible assets changed year-over-year?
Emergent Biosolutions's amortization of capitalized software and acquired intangible assets increased by 1.2% year-over-year, from $16.3M to $16.5M.
What is the long-term trend for Emergent Biosolutions's amortization of capitalized software and acquired intangible assets?
Over 4 years (2021 to 2025), Emergent Biosolutions's amortization of capitalized software and acquired intangible assets has grown at a 2.7% compound annual growth rate (CAGR), from $58.5M to $65.1M.